CapsoVision Inc. (CV)
CV trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/0001378325-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CV on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0001378325 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $13.6M |
| Net income | -$25.3M |
| Operating income | -$25.5M |
| Net margin | -186.8% |
| Operating margin | -188.3% |
| Revenue growth | +15.3% |
| Cash | Not in SEC XBRL data |
| Total assets | $18.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 25.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The Company, having evaluated the extant facts and circumstances, concluded that the facts and circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date of issuance of these financial statements." | 10-Q 2026-11-12 |
| Cash and burn | not enough data | Report 2026-09-30 |
| Shares outstanding | 53,609,719 (2026-11-11); 46,843,225 a year earlier. | Cover page 2026-11-11 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-09-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Baker Tilly US, LLP, Santa Clara, California, United States | PCAOB Form AP 2026-04-22 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $16.0M, sold $9K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $3.6M | -$7.3M | -$7.0M | Not filed | No debt tags | $13.9M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $3.6M | -$7.5M | -$8.4M | Not filed | No debt tags | $13.9M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $2.8M | -$7.0M | -$6.1M | Not filed | No debt tags | $13.6M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $3.9M | -$7.4M | -$7.7M | Not filed | No debt tags | $13.6M | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $3.5M | -$7.9M | -$5.7M | Not filed | No debt tags | $13.1M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $3.3M | -$4.6M | -$4.5M | Not filed | No debt tags | $12.5M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $2.8M | -$5.4M | -$5.0M | Not filed | No debt tags | $12.0M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $3.5M | -$4.6M | -$5.4M | Not filed | No debt tags | $11.8M | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-18 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 143 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.6% |
| 1 month | -11.1% |
| 3 months | -11.2% |
| Year to date | -43.6% |
| 1 year | +6.3% |
| From 52-week high | -58.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELMD | Electromed Inc. | $23.10 | -5.02% | $188.8M |
| INMD | InMode Ltd. | $13.15 | -0.90% | $755.9M |
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
| CBLL | CeriBell Inc. | $26.42 | +1.07% | $1.0B |
| HSDT | Solana Company Class A Common Stock (DE) | $1.64 | -5.20% | $103.1M |
| VANI | Vivani Medical Inc. Common Stock (DE) | $1.02 | +0.99% | $92.0M |
| CNMD | CONMED Corporation | $49.35 | -2.45% | $1.5B |
| STXS | Stereotaxis Inc. | $0.8027 | -4.80% | $80.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier